Enliven Therapeutics, INC Form 4 insider transactions

Mika K Derynck, a Director of Enliven Therapeutics, Inc., sold 158,795 shares of common stock on August 4, 2026 for $60.21 per share.

Benjamin Hohl, CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc., sold 6,018 shares of common stock on July 17, 2026.

Helen Louise Collins, CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc., sold 5,000 shares of common stock on July 17, 2026.

Director Lori Kunkel reported a sale of Enliven Therapeutics, Inc. common stock totaling 10,000 shares, executed under a Rule 10b5-1 trading plan.

OrbiMed Advisors LLC, along with affiliated entities, has reported significant transactions and beneficial ownership changes related to Enliven Therapeutics, Inc. (ELVN).

OrbiMed Advisors LLC reported the sale of 281,408 shares of Enliven Therapeutics, Inc. common stock at a price of $45.02 per share.

Enliven Therapeutics Director Lori Kunkel sold 10,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc., reported transactions involving the acquisition and disposition of company common stock and stock options on May 18, 2026, executed under a Rule 10b5-1 trading plan.

Chief Medical Officer Helen Louise Collins exercised options and sold 5,000 shares of Enliven Therapeutics common stock.

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised stock options and sold 40,000 shares of common stock under a pre-arranged trading plan.

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised stock options and subsequently sold 5,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics Director Richard A. Heyman sold 1,230 shares of common stock for $26.1759 per share under a pre-arranged trading plan.

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised options and sold 45,000 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P Lyssikatos, sold 5,000 shares of common stock for a weighted average price of $29.0438 per share.

Enliven Therapeutics' Chief Scientific Officer, Joseph P Lyssikatos, sold 20,000 shares of common stock on January 20, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Director Richard A. Heyman sold 1,230 shares of common stock on January 20, 2026, through a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 48,300 shares of common stock for approximately $1.35 million through a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 132,500 shares of common stock for approximately $3.47 million in early January 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics Director Richard A. Heyman reported the sale of common stock totaling 13,920 shares through pre-arranged Rule 10b5-1 trading plans in early January 2026.

Enliven Therapeutics Director J. Scott Garland was granted 59,372 stock options at an exercise price of $15.47, vesting monthly over three years.

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, exercised 13,000 stock options, acquiring common stock.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 5,000 shares of common stock for a weighted average price of $16.8412 per share.

Enliven Therapeutics Director Lori Anne Kunkel exercised 15,958 stock options at $1.12 per share, increasing her direct common stock holdings.

Enliven Therapeutics' President and CEO, Richard A. Fair, was granted 875,000 stock options with an exercise price of $18.77, vesting over several years.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,663 shares of common stock on December 8, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock on November 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' President and CEO, Samuel Kintz, sold 12,500 shares of common stock for a weighted average price of $21.8191 per share.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold common stock totaling 6,667 shares on November 7, 2025, under a pre-arranged 10b5-1 trading plan.

Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 12,500 shares of common stock for a weighted average price of $22.082 per share.

Enliven Therapeutics' President and CEO, Samuel Kintz, sold 12,500 shares of common stock for approximately $21.33 per share under a pre-arranged trading plan.